ArticleBMC psychiatry2026
Potential biomarkers differentiating major depression from bipolar disorder depressive episodes by Olink Proteomics.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
designA prospective study.
backgroundIn clinical practice, it is challenging to tell major depressive disorder (MD-D) apart from bipolar disorder depressive episodes (BD-D). This study focuses on using inflammatory proteins as biomarkers to differentiate MD-D from BD-D. MATERIALS AND
methodsAdmission plasma was collected from 30 healthy participants, 30 BD-D patients, and 30 MD-D patients. Ten samples from each group were randomly chosen for analysis using Olink Proteomics, and all samples were confirmed with ELISA. Then, we established a nomogram prediction model to assess the diagnostic potential biomarkers and their cut-off points.
resultsThe study revealed that patients with MD-D exhibited notably elevated levels of IL6, MCP-3, TGF-α, TNFRSF9, and IL17-A compared to healthy control, with their cut-off values being 2.705 pg/ml, 374.5 pg/ml, 51.5 pg/ml, 328.5 pg/ml, and 2.905 pg/ml, respectively. Significantly higher levels of IL17-A and IFN-γ were found in MD-D patients compared to BD-D individuals and their cut-off values were 3.645 pg/ml, and 40.4 pg/ml, respectively. Subsequently, we created a nomogram prediction model that exhibited excellent consistency in the correction curve and proved to be clinically practical based on decision curve analysis.
conclusionsOur research indicated plasma inflammatory proteins associated with MD-D and could serve as potential biomarkers for it. Moreover, we discovered their cut-off values. A prediction model was created by us to accurately predict MD-D from BD-D patients, giving clinicians a novel approach to quickly distinguish MD-D and implement early targeted treatments. Larger samples are also necessary to further verify our results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.